Brookline upgraded Rein Therapeutics (RNTX) to Buy from Hold with a $6 price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNTX:
- Rein Therapeutics Resumes Phase 2 Trial for LTI-03
- Rein Therapeutics receives FDA clearance to resume Phase 2 trial of LTI-03
- Rein Therapeutics Secures Third Pre-Paid Advance
- Rein receives European regulatory approval to initiate Phase 2 trial of LTI-03
- Rein Therapeutics initiated with a Buy at H.C. Wainwright